MANE
Veradermics, Incorporated
$45.03
+4.95%
2026-02-27
About Veradermics, Incorporated
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.
Key Fundamentals
Forward P/E
-35.84
EPS (TTM)
$-2.37
ROE
-72.1%
Profit Margin
0.0%
Debt/Equity
0.00
Market Cap
$4.46B
Avg Volume (10D)
1.2M
Recent Breakout Signals
No recent breakout signals detected for MANE.
Recent Price Range (60 Days)
60D High
$51.56
60D Low
$32.00
Avg Volume
487K
Latest Close
$45.03
Get breakout alerts for MANE
Sign up for Breakout Scanner to receive daily notifications when MANE triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Veradermics, Incorporated (MANE) is listed on the New York Stock Exchange (NYSE). Breakout Scanner monitors MANE daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. MANE operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.